Venetoclax (INN, trade name Venclexta ven-KLEKS-tuh, previously known as GDC-0199, ABT-199, and RG7601) is a small molecule oral drug being investigated to treat chronic lymphocytic leukemia (CLL). In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for patients with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation.

CAS：1257044-40-8
中文别名：维奈妥拉;
英文别名：Venclexta (US Trade name);Venclyxto (EU Trade name);GDC-0199;ABT-199;RG7601;4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;GDC0199;CS-1155;UNII-N54AIC43PW;
分子式：C45H50ClN7O7S
分子量：868.439
精确质量：867.318
Psa：183.09
Logp：10.7307

UNII：N54AIC43PW